The immune cell engineering market involves engineering techniques to modify cells of the immune system such as T cells,NK cells, dendritic cells etc. to fight diseases. This involves extraction of immune cells from patient's blood, enhancing their ability to recognize and attack cancer cells outside the body and then infusing them back into the patient's bloodstream. CAR-T cell therapy is one such approach where T-cells are extracted, engineered with chimeric antigen receptors (CARs) recognizing tumor antigens and infused back to treat cancers like leukemia and lymphoma. The advantages of CAR-T cell therapy include its high efficacy against certain blood cancers with durable response even in relapsed/refractory patients.

The global immune cell engineering market size is expected to reach US$ 14.30 Bn by 2031, from US$ 3.45 Bn in 2024, at a CAGR of 22.5% during the forecast period.

Key Takeaways

Key players operating in the immune cell engineering are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. The majority share of the market is captured by Gilead Sciences Inc. due to its dominant position in CAR T-cell therapy drug Yescarta and Kite Pharma acquisition in 2017.

The Immune Cell Engineering Market Trends is witnessing high growth owing to increasing demand for CAR T-cell therapy in treating hematologic cancers. The approval and commercialization of Novartis' Kymriah and Gilead's Yescarta have boosted the CAR T-cell therapy market. Furthermore, the growing clinical trials and pipeline drugs will further drive the market during the forecast period.

Several technological advancements have been made in the field of immune cell engineering such as next-generation CAR T-cell therapy using armored CARs, inverted CARs, TanCARs, etc. to enhance efficacy and safety. Combination therapies of CAR T cells with monoclonal antibodies, chemotherapy and immune checkpoint inhibitors are being investigated to improve outcomes.

Market Trends

1. Growing Focus on Solid Tumors: Major Players In Immune Cell Engineering Market  are focusing on developing CAR T-cell therapies for solid tumors like lung cancer, breast cancer and prostate cancer to expand indications beyond hematological cancers.

2. Multi-Antigen CAR T Cells: Researchers are developing multi-antigen CAR T cells targeting multiple antigens expressed on tumor cells to prevent antigen escape.

Market Opportunities

1. Asia Pacific Region: The APAC region offers significant growth opportunities owing to growing healthcare expenditure, presence of lucrative contract manufacturing hubs and expanding clinical trials in countries like China and India.

2. Combination Therapies: Combining CAR T cells with immune checkpoint inhibitors, biomodulators, and other drugs offers scope for enhancing efficacy and response rates.

Impact of COVID-19 on Immune Cell Engineering Market Growth

The COVID-19 pandemic has significantly impacted the growth of the immune cell engineering market. During the initial outbreak period, research activities related to immune cell engineering were obstructed due to lockdowns and disruptions in supply chains. Many clinical trials were halted which impacted the development of new therapies. However, with COVID-19 highlighting the importance of the immune system, research in this field gained more attention and funding in the later stages of the pandemic.

Various companies accelerated their research to develop immune cell therapies against COVID-19. Adaptive biotechnologies and Cellarity launched research initiatives to engineer immune cells that can target SARS-CoV-2. Many ongoing clinical trials also included COVID-19 patients to test immune cell therapies. The pandemic demonstrated the need for new treatment strategies and highlighted the potential of immune cell therapies.

as per Immune Cell Engineering Market Size and Trends activities resumed post lockdowns, the demand is projected to increase significantly in the forecast period. Increased government funding and collaboration between research institutes are expected to drive the market. Companies are also exploring various technology platforms like CRISPR to develop more efficient and personalized immune cell engineering approaches. While short term growth was limited during pandemic, long term outlook remains positive due to elevated interest in cell and gene therapies post COVID-19.

Geographical Regions with Highest Immune Cell Engineering Market Value

North America has been the largest regional market for immune cell engineering accounting for over 40% of the global value. Presence of major players, robust research infrastructure and increasing adoption of new cell therapies have contributed to market concentration in the US and copyright.

Asia Pacific is projected to be the fastest growing region during the forecast period. This can be attributed to rising healthcare spending, expanding research bases of global companies and growing diagnostics and biopharmaceutical industries in China, Japan and India. Growing treatment needs, increasing disposable income and focus of regional players on immune therapies make Asia Pacific an attractive market for future growth.

Get More Insights on Immune Cell Engineering Market

Discover the Report for More Insights, Tailored to Your Language.

French German Italian Russian Japanese Chinese Korean Portuguese

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)